1612148-60-3

Basic information

• Product Name: 2-({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricycle-[3.3.1.13,7]decane-2-carboxylic acid
• Synonyms: 2-({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricycle-[3.3.1.13,7]decane-2-carboxylic acid
• CAS NO: 1612148-60-3
• Molecular Weight: 519.573
• Mol File: 1612148-60-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricycle-[3.3.1.13,7]decane-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricycle-[3.3.1.13,7]decane-2-carboxylic acid(1612148-60-3)
• EPA Substance Registry System: 2-({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricycle-[3.3.1.13,7]decane-2-carboxylic acid(1612148-60-3)

Safety Data

• Hazardous Substances Data: 1612148-60-3(Hazardous Substances Data)

Upstream product

• 1612148-78-3 methyl 5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylate 
• 1612148-85-2 5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylic acid 
• 50294-51-4 2-(amino)tricyclo[3.3.1.13,7]decane-2-carboxylic acid hydrochloride 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 42381-05-5 2-amino-2-adamantanecarboxylic acid 
• 2040-04-2 2,6-dimethoxyacetophenone 

Relevant articles and documents

Discovery of a novel small molecule agonist scaffold for the APJ receptor

The apelinergic system includes a series of endogenous peptides apelin, ELABELA/TODDLER and their 7-transmembrane G-protein coupled apelin receptor (APJ, AGTRL-1, APLNR). The APJ receptor is an attractive therapeutic target because of its involvement in cardiovascular diseases and potentially other disorders including liver fibrosis, obesity, diabetes, and neuroprotection. To date, pharmacological characterization of the APJ receptor has been limited due to the lack of small molecule functional agonists or antagonists. Through focused screening we identified a drug-like small molecule agonist hit 1 with a functional EC50value of 21.5?±?5?μM and binding affinity (Ki) of 5.2?±?0.5?μM. Initial structure–activity studies afforded compound 22 having a 27-fold enhancement in potency and the first sub-micromolar full agonist with an EC50value of 800?±?0.1?nM and Kiof 1.3?±?0.3?μM. Preliminary SAR, synthetic methodology, and in vitro pharmacological characterization indicate this scaffold will serve as a favorable starting point for further refinement of APJ potency and selectivity. [Figure presented]

Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3- yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound

Compounds active at neurotensin receptors (NTS1 and NTS2) exert analgesic effects on different types of nociceptive modalities, including thermal, mechanical, and chemical stimuli. The NTS2 preferring peptide JMV-431 (2) and the NTS2 selective nonpeptide compound levocabastine (6) have been shown to be effective in relieving the pain associated with peripheral neuropathies. With the aim of identifying novel nonpeptide compounds selective for NTS2, we examined analogues of SR48692 (5a) using a FLIPR calcium assay in CHO cells stably expressing rat NTS2. This led to the discovery of the NTS2 selective nonpeptide compound 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl] carbonyl}amino)cyclohexane carboxylic acid (NTRC-739, 7b) starting from the nonselective compound 5a.